百济神州：港股公告：百济神州有限公司截至2023年9月30日止三个月及九个月未经审核业绩以及业务进展最新情况
BeiGene, Ltd.
06160
2023930
13.09
571XIVA
2023930
2023930
2023
2023119
1995(Private Securities LitigationReform Act of 1995)
10-Q
20231110
Margaret Han DuganDonald W. GlazerMichael GollerAnthony C. HooperRanjeev KrishanaThomas MalleyAlessandro RivaCorazon (Corsee) D. Sanders
2023? 7.815.95
102%70%?
?
3.58
130%?
?
(ESCC)
BGNE06160688235
2023
(John V. Oyler)
?
(CLL)
?
?
?
3.577130%CLL
? (CHMP)
?(R/R)(FL)
?
?
R/R CLL?
?
? (EC)
?
ESCC? (FDA)
?(BLA)ESCC
(PDUFA)FDA20247
2023
20239307.8132022
3.876101.6%
(1)
9309302023202220232022
$$$$398,229133,431815,059347,180270,084108,104632,391264,373128,14525,327182,66882,807287,935233,077831,399636,241284,981233,077825,809636,241
2,954–5,590–
85,58317,995153,27346,634
30,6645,20076,4879,205
54,91912,79576,78637,4299,5613,12524,6395,771781,308387,6281,824,3701,035,826
(1)
20239305.9532022
3.49570.3%? 20232.458
??? 2023
?
2.701
149.8%(TN)R/R CLL(SLL)FDA
?
4,740
20.8%
(BTK)
? 2023
?
1.444
12.6%
?
PD-1
?
202383.8%
78.1%
??
20239308.19020227.4949.3%
20239302.15420225.576
(BMS)3.629
3.044
?
20239300.160.15
(ADS)2.062.0120229300.41ADS5.39
202393032202212314520239307,820
5.619
2023
202310-Q
?
? 3ALPINE
?
R/R CLL
?(PFS)? (EMA)
(CHMP)
R/R(FL)? 13TNR/
R CLL?
R/R CLL
?
R/R(WM)? FDA?
? EC
ESCC
?
?
(NMPA)?
? FDA
?ESCCBLAPDUFAFDA2024
? NMPA
?(sBLA)PD-(L)1?
(ES-SCLC)sBLANMPA?
? 3RATIONALE-315
(EFS)
??IIIIIA(NSCLC)Sonrotoclax (BGB-11417)
? R/R WM? (NME)1
BCL2CCR8(mAb)DGKHPK1
?
? 3ALPINE
?R/R CLL/SLLPFS
2023FDA? (sNDA)
20243FDA
R/R FL
?
? 20232024
FDAESCC? FDA
ESCC
(PDUFA)20247? 2024
EMA
NSCLCNSCLC?
? 2023FDA
(sBLA)? 2024
(PMDA)ESCC
? 2024
NMPA
??
IIIIIANSCLCsBLA? 2024EMA
ESCCsBLA
?
? 20233
ALPINE
??
R/R CLL/SLL
Sonrotoclax? 2023
?
CLLBTK CDAC (BGB-16673)
? 202312
(ASH)B
TIGIT
? 2024
NSCLC3AdvanTIG-302
? 122023ASH243ALPINE
??
R/R CLL/SLL?
sonrotoclaxTN CLL1/2? 2023(ESMO)105
o
?
(GC/GEJC)3RATIONALE-305o 3RATIONALE-315
?II-IIIA(NSCLC)? 2023
?ES-SCLC3RATIONALE-312
?
1009.3
2024
? 64,000
(ADC)?
55.95.2
? Zymeworks
HER2ZW49(zanidatamabzovodotin)
202320229301231
$ 3,187,881$ 4,540,288
309,079173,168316,929282,3461,178,038845,9465,524,8796,379,290341,857294,781505,824467,352
300255,887255,391293,960531,051538,1171,761,6451,995,935$ 3,763,234$ 4,383,355
ADSADS
9309302023202220232022
$ 595,290$ 349,506$ 1,559,326$ 915,590
186,01838,122265,044120,236781,308387,6281,824,3701,035,826
96,30976,543274,088212,953453,259426,3631,284,6071,194,485364,421322,8921,087,954948,868
1,2871871,662563915,276825,9852,648,3112,356,869(133,968)(438,357)(823,941)(1,321,043)
26,64912,75957,73534,261336,657(125,640)291,142(243,290)229,338(551,238)(475,064)(1,530,072)
13,9256,31839,09128,408215,413(557,556)(514,155)(1,558,480)
$ 0.16$ (0.41)$ (0.38)$ (1.16)$ 0.15$ (0.41)$ (0.38)$ (1.16)1,360,716,2791,345,303,7471,358,392,4701,337,976,8531,390,331,8331,345,303,7471,358,392,4701,337,976,853ADS
$ 2.06$ (5.39)$ (4.92)$ (15.14)$ 2.01$ (5.39)$ (4.92)$ (15.14)ADS
104,670,483103,484,904104,491,728102,921,296106,948,603103,484,904104,491,728102,921,296
10,000 www.beigene.com.cn
1995(Private Securities LitigationReform Act of 1995)
10-Q
+86 10 5895 8058+86 21 31591070ir@beigene.commedia@beigene.com